466 related articles for article (PubMed ID: 9000632)
21. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
22. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Chan JH; Kleim JP; Stammers DK
J Med Chem; 2007 May; 50(10):2301-9. PubMed ID: 17441703
[TBL] [Abstract][Full Text] [Related]
23. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
24. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
[TBL] [Abstract][Full Text] [Related]
25. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
Esnouf R; Ren J; Ross C; Jones Y; Stammers D; Stuart D
Nat Struct Biol; 1995 Apr; 2(4):303-8. PubMed ID: 7540935
[TBL] [Abstract][Full Text] [Related]
27. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.
Ding J; Das K; Moereels H; Koymans L; Andries K; Janssen PA; Hughes SH; Arnold E
Nat Struct Biol; 1995 May; 2(5):407-15. PubMed ID: 7545077
[TBL] [Abstract][Full Text] [Related]
28. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
29. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
30. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
[TBL] [Abstract][Full Text] [Related]
31. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
32. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.
Paris KA; Haq O; Felts AK; Das K; Arnold E; Levy RM
J Med Chem; 2009 Oct; 52(20):6413-20. PubMed ID: 19827836
[TBL] [Abstract][Full Text] [Related]
33. Identification of Adjacent NNRTI Binding Pocket in Multi-mutated HIV1- RT Enzyme Model: An in silico Study.
Kamil RF; Debnath U; Verma S; Prabhakar YS
Curr HIV Res; 2018; 16(2):121-129. PubMed ID: 29651941
[TBL] [Abstract][Full Text] [Related]
34. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
[TBL] [Abstract][Full Text] [Related]
35. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action.
Kroeger Smith MB; Michejda CJ; Hughes SH; Boyer PL; Janssen PA; Andries K; Buckheit RW; Smith RH
Protein Eng; 1997 Dec; 10(12):1379-83. PubMed ID: 9542999
[TBL] [Abstract][Full Text] [Related]
36. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site.
Sharaf NG; Xi Z; Ishima R; Gronenborn AM
Proteins; 2017 Dec; 85(12):2191-2197. PubMed ID: 28905420
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
38. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
39. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.
Zhang H; Vrang L; Bäckbro K; Lind P; Sahlberg C; Unge T; Oberg B
Antiviral Res; 1995 Dec; 28(4):331-42. PubMed ID: 8669892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
